[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612803":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Antonio Farina, MD","CONTACT","0512144377","antonio.farina@unibo.it",[15,29],{"facility":5,"status":16,"city":17,"state":17,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"RECRUITING","Bologna","40138","Italy","IT",{"type":22,"coordinates":23},"Point",[24,25],11.33875,44.49381,{"lat":25,"lon":24},[28],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":19,"countryCode":20,"cosmosGeoPoint":35,"geoPoint":39,"contacts":40},"IRCCS Ca' Granda Ospedale Maggiore Policlinico","NOT_YET_RECRUITING","Milan","Milano","20122",{"type":22,"coordinates":36},[37,38],12.59836,42.78235,{"lat":38,"lon":37},[41],{"name":42,"role":11,"phone":43,"phoneExt":7,"email":44},"Irene Cetin, MD","0255032240","irene.cetin@unimi.it",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100612803","screening-for-intrapartum-fetal-compromise-using-placental-biomarkers-100612803",false,"NCT07258329","Screening for Intrapartum Fetal Compromise Using Placental Biomarkers","Screening Della Compromissione Fetale Intrapartum Mediante Utilizzo Dei Marcatori Placentari","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Gestational age ≥ 32 weeks\n* Obtaining informed consent for participation in the study and for the processing of personal data\n* Pregnant patients with an indication to perform placental marker testing as part of routine clinical practice\n* Patients who will deliver at the Obstetrics Units of the participating centers\n\nExclusion Criteria:\n\n\\- Absolute contraindications to vaginal delivery (placenta previa, vasa previa, placenta accreta, previous myomectomy)","FEMALE","18 Years",{"count":57,"type":58},428,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1\u002FPlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing.",[62],"Pregnant Women","2025-11-26",{"date":65,"type":66},"2025-12-02","ACTUAL",{"date":68,"type":66},"2025-03-28",{"date":70,"type":58},"2028-10-01",{"name":5,"class":6},2]